Navigation Links
Study shows that high-dose, high-frequency interferon produces no additional benefit
Date:4/15/2008

CAMBRIDGE, MA April 15, 2008 -- Results of a phase IV, open label, head-to-head study of intramuscular AVONEX and high-dose, high-frequency subcutaneous Rebif (interferon beta-1a) provide clinical evidence that the two drugs show similar efficacy over 18 to 30 months of continued therapy in patients with relapsing-remitting multiple sclerosis (RRMS). These data are published in the April 2008 issue of the Current Medical Research and Opinion journal.

The Prospective and Retrospective Long-Term Observational Study of AVONEX and Rebif (PROOF), involved 217 patients with 136 completing a median of 25.9 months of AVONEX 30 mcg once weekly (n=69) and a median of 22.2 months Rebif 44 mcg three times weekly (n=67).

Led by a group of principal investigators including Dr. T. Jock Murray of Division of Neurology, Dalhousie MS Research Unit, Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia; Canada; and Dr. Alireza Minagar, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana, the study provides further clinical evidence that the dose and frequency of treatment shows no advantage on delivering better efficacy.

Upon evaluation of baseline disability, Expanded Disability Status Scale (EDSS) scores showed no statistically significant differences between the two treatment groups during the prospective portion of the study, with sustained disability progression similar for both: 25.8 percent for AVONEX vs. 26.7 percent for Rebif. Additional key findings include:

  • Relapse rates, MRI endpoints of brain parenchymal fraction, T1 lesion volume, T2 lesion volume, number of new/enlarging T2 lesions and gadolinium enhancing (Gd+) lesion volume and count were also comparable between both groups.

  • In addition, 19 percent of patients taking Rebif tested positive for neutralizing antibodies (NAbs) at end of treatment compared with zero percent taking AVONEX.

Given that this data shows similar efficacy between AVONEX and Rebif, physicians and patients with relapsing-remitting MS may want to consider factors that influence ease of use and adherence to treatment such as convenient administration, injection tolerability and immunogenicity when selecting therapy, said Dr. Murray.

These results are in accordance with a growing body of evidence from other trials that suggest that interferons show similar efficacy regardless of dose or frequency, said Thorsten Eickenhorst, MD, vice president of Medical Affairs at Biogen Idec. AVONEX is the only once-a-week therapy that has proven to slow disability and offers a low incidence of injection site reactions.

AVONEX is the number one prescribed treatment for relapsing forms of multiple sclerosis (MS) worldwide, and is the only once-a-week MS therapy that is effective after the first attack. AVONEX is also proven to slow the progression of physical disability (as shown by 37 percent reduction over two years) and reduce the number of relapses. Nearly nine out of 10 patients remained fully functional after five years. AVONEX has been proven effective in clinical trials for up to three years.


'/>"/>

Contact: Kathleen Vigneault
kathleen.vigneault@mslpr.com
Manning Selvage & Lee
Source:Eurekalert

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... Santa Clara, Calif. (PRWEB) , ... May 26, ... ... technology, announces the integration of the CareFusion NOX-T3 portable sleep monitor with its ... that provides a consistent, browser-based interface for diagnostic device operations. With this platform, ...
(Date:5/26/2017)... , ... May 26, 2017 , ... After raising nearly ... Top gadget will continue to be available at a discounted crowdfunding price on ... stress wherever they are, I also wanted to bring a fidget toy to the ...
(Date:5/26/2017)... ... May 26, 2017 , ... “When the Stars Lead Home”: ... the creation of published author Laura Weigel Douglas, an avid reader who lives in ... house that sometimes feels like Green Hills Adventure Camp. She couldn’t be more grateful. ...
(Date:5/26/2017)... ... 26, 2017 , ... Water damage to the flooring of several classrooms at ... education officials with a number of critical issues to address before students could return ... accomplished with little or no disruption to class schedules. Second, the project had to ...
(Date:5/24/2017)... San Diego, California (PRWEB) , ... May 24, ... ... patient care through innovative medical image management and interpretation, has received U.S. Food ... technology. , Nucleus.io is a web-based, scalable and secure cloud platform for ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... , May 4, 2017  DarioHealth Corp. (NASDAQ: DRIO), ... and big data solutions, today announced that it is ... and STI Technologies Limited to lower diabetes healthcare costs ... STI,s innoviCares card, which is available throughout all provinces ... customers will be eligible for additional savings when shopping ...
(Date:5/4/2017)... Wash. , May 4, 2017   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... media ("BioLife" or the "Company"), today announced that the ... after market close on Thursday, May 11, 2017, and ... live webcast at 1:30 p.m. PT that afternoon. Management ...
(Date:5/3/2017)... , May 3, 2017  Kalorama Information ... of nine percent next year and this is ... and hematopoietic stem cell (HSCT) or bone marrow ... testing technologies are well-suited for this task. This ... research publisher Kalorama Information. The various PCR-based methodologies, ...
Breaking Medicine Technology: